Introduction
============

Cerebral infarction is a common disease of the central nervous system, accounting for 75--80% of cerebrovascular disease, with a high rate of morbidity and mortality ([@b1-br-0-0-692]). Family history of cerebral infarction, age, diabetes and atherosclerosis were some of the major risk factors of cerebral infarction. The morbidity of cerebral infarction in men \>55 years or women \>60 years of age was much higher than that of other age groups ([@b2-br-0-0-692]). Massive cerebral infarction occurs primarily due to the cerebral arterial main trunk block that causes greater tissue damage range and a higher degree of risk ([@b3-br-0-0-692]).

Urinary kallidinogenase and edaravone are a new selective cerebral vasodilator and oxygen-free radical scavenger, which have recently been used for the treatment of cerebral infarction and are considered effective ([@b4-br-0-0-692]).

In the present study, the application of urinary kallidinogenase and edaravone for the treatment of massive cerebral infarction was assessed to enhance the clinical curative effect of massive cerebral infarction.

Materials and methods
=====================

### Cases

A total of 58 patients with massive cerebral infarction were admitted to the Hospital between January 2013 and January 2014, and were examined and diagnosed using computed tomography (CT) or magnetic resonance imaging (MRI). Patients with systemic complications, severe bleeding tendency, severe liver and kidney dysfunction, other serious organic diseases, drug allergy in the study, and cerebral hemorrhage identified by CT or MRI examination were excluded. Patients or their families participated voluntarily, were provided with information regarding the study, and provided written informed consent. The study was approved by the ethics committee of Xuzhou City Center Hospital. The patients were randomly divided into the observation and control groups, with 29 cases in each group. In total, 18 men and 11 women were included in the observation group. The patient age range was 44--80 years, with an average age of 53.67±7.24 years. Complications identified included 22 cases of hypertension and 12 cases of diabetes. The control group subjects included 16 men and 13 women, with an age range of 45--78 years, and an average age of 54.13±8.22 years. Complications for the control group included 21 cases of hypertension and 10 cases of diabetes. No significant differences were identified between the two groups with regard to age, gender, and complications (P\>0.05), making these parameters comparable.

### Method

The patients in the two groups received basic treatment, in the form of oral administration of aspirin (300 mg/day), which was reduced to 100 mg/day after 10 days of continuous medication and oral atorvastatin, 20 mg once daily. Blood glucose and blood pressure were controlled for patients with hypertension and hyperglycemia. However, use of angiotensin converting enzyme inhibitors of antihypertensive drugs were disallowed during the application of urinary kallidinogenase. Patients in the control group received edaravone 30 mg+100 ml 0.9% NaCl injection solution by intravenous drip, four times daily. Subsequently, 0.15 PNA dissolved in 0.9% 100 ml NaCl solution was intravenously administered once daily in the observation group on the basis of treatment of the control group. Patients in the two groups were treated for 14 days as a course of treatment.

### Observation index

Venous blood samples of the two groups were collected prior to 14 days after treatment, respectively. The vascular endothelial growth factor (VEGF) level was detected with the application of ELISA, and the serum high-sensitivity C-reactive protein (hs-CRP) level was analyzed with immune turbidimetry following conventional centrifugal separation. Adverse reactions of the two groups were observed during the treatment.

Liver and renal function and blood and urine routine examination were conducted prior to treatment and 14 days after treatment, respectively.

### Standard of curative effect

'Scoring criteria of clinical neurological deficit for patients with stroke' set by the Chinese Society for Neuroscience were used to assess patients with neurological deficits and the curative effect according to the National Institutes of Health Stroke Scale (NIHSS) ([@b5-br-0-0-692]). Scoring was carried out as indicated by NIHSS: basic cure, reduction by 91--100% with a clinical disability degree of level 0; marked improvements, decreased by 46--90% with a clinical disability degree of level 1--3; progress, reduction by 18--45%; no change, decrease or increase of \<17%; and deterioration, increase of \>18%. The total efficiency was shown as cases of (basic cure + marked improvement + progress)/total cases × 100%.

### Statistical analysis

Data were analyzed using SPSS 18.0 statistics software (IBM SPSS, Armonk, NY, USA). Measurement data were presented as mean ± standard deviation using the t-test. Enumeration data were presented by rate (%) using the χ^2^ test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Changes of serum VEGF and hs-CRP before and after the treatment

Serum VEGF and hs-CRP levels of the two groups had no significant difference before treatment (P\<0.05). Serum VEGF levels in the two groups were significantly increased after treatment and serum VEGF in the observation group was significantly higher than that of the control group. hs-CRP of the two groups was significantly decreased and hs-CRP of the observation group was significantly lower than those of the control group (P\<0.05, [Table I](#tI-br-0-0-692){ref-type="table"}).

### Changes of NIHSS score before and after treatment

NIHSS scores of the two groups were not significantly different before treatment (P\>0.05). NIHSS scores of the two groups were significantly decreased after treatment (P\<0.05). NIHSS scores of the observation group were significantly lower than that of the control group (P\<0.05, [Table II](#tII-br-0-0-692){ref-type="table"}).

### Clinical curative effect

#### Adverse reactions

One patient in the observation group had a mild decrease of blood pressure and was relieved by symptomatic treatment. The control group showed no adverse reaction. Blood and urine routine, liver, and kidney function had no obvious abnormalities in the two groups before and after treatment. No significant differences of adverse drug reaction were observed between the two groups (P\>0.05, [Table III](#tIII-br-0-0-692){ref-type="table"}).

Discussion
==========

Massive cerebral infarction refers mainly to complete stroke of the middle cerebral artery, carotid artery, or cerebral cortical branches and is mainly marked by progressive contralateral gaze palsy, contralateral complete limb hemiplegia, and unilateral sensory disturbance ([@b6-br-0-0-692]). It usually shows obvious brain edema and intracranial hypertension at the same time and may develop into brain herniation ([@b7-br-0-0-692],[@b8-br-0-0-692]). Drug treatment is one of the means used for the clinical treatment of massive cerebral infarction. Thrombolytic therapy is considered an effective method for the treatment of ultra-early cerebral infarction ([@b9-br-0-0-692]). However, it has a limited therapeutic time window. Thrombolytic therapy can achieve noteworthy results only when used within 3.0--4.5 h of occurence ([@b9-br-0-0-692]). Cerebral infarction also tends to be acute. Thus, the use of thrombolytic therapy is always accompanied with high risk and its application is restricted ([@b8-br-0-0-692],[@b10-br-0-0-692]--[@b12-br-0-0-692]). Previous findings have shown that only \<3% of the massive cerebral infarction patients can receive thrombolytic therapy in a timely manner. However, most patients did not undergo thrombolytic treatment ([@b13-br-0-0-692],[@b14-br-0-0-692]). Therefore, it is imperative to identify a more effective therapy with longer treatment time.

In the early stage of cerebral infarction, the brain tissue in the cerebral infarction region experiences metabolic acidosis due to severe hypoxia ischemia. Intracellular calcium overloads significantly, generating a large amount of oxygen-free radical. Oxygen-free radicals are thought to be the main physiological and pathological basis of cerebral infarction ([@b15-br-0-0-692],[@b16-br-0-0-692]). Ischemia reperfusion injury occurred after cerebral infarction. Lipid soluble radical, hydroxyl radical, and superoxide anion-based toxic-free radicals are produced, which directly cause oxidative damage of intracellular lipid, protein, and nucleic acid and can mediate an ischemic cascade reaction to induce neuronal cell apoptosis and edema ([@b17-br-0-0-692],[@b18-br-0-0-692]). Therefore, the key to the treatment of large area cerebral infarction lies in improving ischemia, inhibiting, and scavenging oxygen-free radicals.

Edaravone is a new type of antioxidant and free radical scavenger. It has potent hydroxyl radical, active oxygen molecule scavenging ability, and anti-lipid peroxidation effect. Consequently, it can inhibit the cerebral edema and brain tissue injury process it involved ([@b11-br-0-0-692],[@b14-br-0-0-692]). In addition, it can effectively alleviate the degree of injury of vascular endothelial cells of the ischemic region, improving the neuronal cell hypoxia tolerance to alleviate the local cerebral edema and reduce the infarct. Edaravone has an inhibitory effect on delayed neuronal apoptosis, which can effectively protect the patients\' nerve function ([@b19-br-0-0-692],[@b20-br-0-0-692]). Blood-brain barrier permeability for edaravone is \~60%. Its intravenous injection can effectively remove cytotoxic hydroxyl-free radicals and effectively inhibit the irreversible damage to nucleic acid, and protein damage mediated by peroxyl radical ([@b16-br-0-0-692]--[@b18-br-0-0-692]). Kimura *et al* ([@b18-br-0-0-692]) administered the auxiliary treatment of edaravone to 40 cases of patients with massive cerebral infarction and compared that treatment type with conventional symptomatic treatment. The results showed that the NIHSS scores were significantly lower at 14 and 28 days after the auxiliary treatment. The total effective rate was 75%, which was significantly higher than that of the conventional symptomatic treatment (47.5%), confirming its positive effect. Urinary kallidinogenase is tissue human urinary kallikrein extracted from self-urine, which can catalyze the hydrolysis of kininogen and generate kallidin, selectively dilating ischemic artery blood flow, improving the ischemic brain tissue and effectively improving local microcirculation, thereby reducing the infarct ([@b11-br-0-0-692],[@b14-br-0-0-692]). In addition, it can improve the effective rates of the organization utilization for glucose to improve tissue glucose metabolism, and inhibit platelet aggregation and blood coagulation to promote effectively the infarct vascular regeneration ([@b11-br-0-0-692],[@b19-br-0-0-692],[@b20-br-0-0-692]). Two-drug combination has a synergistic effect based on the mechanism of the two drugs, which is expected to improve the treatment effect.

In the present study, the patients in the observation group were treated with urinary kallidinogenase and edaravone combined with traditional treatment, while patients in the control group were administered edaravone and routine treatment. The NIHSS score in the observation group was significantly lower than that of the control group after 14 days of treatment. At the same time, the total effective rate of the observation group was 89.66%, which was significantly higher than 62.07% of the control group. One case in the observation group showed a mild decrease of blood pressure during treatment with no other adverse reactions and good safety.

In summary, urinary kallidinogenase combined with edaravone can improve the nerve function defect of patients in the treatment of massive cerebral infarction with less adverse reaction and obvious curative effect. Thus, it is a safe, reliable and attractive treatment type and worthy of application.

###### 

Changes of serum VEGF and hs-CRP in patients of the two groups before and after the treatment.

                     VEGF (ng/l)    hs-CRP (mmol/l)                                                                                                    
  ------------- ---- -------------- ----------------------------------------------------------------------------------------------------- ------------ ----------------------------------------------------------------------------------------------------
  Observation   29   155.72±53.54   268.51±77.34^[a](#tfn2-br-0-0-692){ref-type="table-fn"},[b](#tfn3-br-0-0-692){ref-type="table-fn"}^   15.02±4.61     9.88±4.82^[a](#tfn2-br-0-0-692){ref-type="table-fn"},[b](#tfn3-br-0-0-692){ref-type="table-fn"}^
  Control       29   154.45±52.19   188.82±57.33^[a](#tfn2-br-0-0-692){ref-type="table-fn"}^                                              14.97±4.56   11.98±4.69^[a](#tfn2-br-0-0-692){ref-type="table-fn"}^

VEGF, vascular endothelial growth factor; hs-CRP, high sensitive C-reactive protein

comparison in the same group before and after treatment, P\<0.05

comparison of the observation group and the treatment group, P\<0.05.

###### 

Comparison of the NIHSS scores of two groups before and after treatment (mean ± standard deviation).

  Groups        Cases   Before treatment   After treatment
  ------------- ------- ------------------ ---------------------------------------------------------------------------------------------------
  Observation   29      22.93±8.29         11.03±3.75^[a](#tfn5-br-0-0-692){ref-type="table-fn"},[b](#tfn6-br-0-0-692){ref-type="table-fn"}^
  Control       29      22.67±7.24         16.58±7.43^[a](#tfn5-br-0-0-692){ref-type="table-fn"}^

NIHSS, National Institutes of Health Stroke Scale

comparison of the group before and after treatment, P\<0.05

comparison between the observation and treatment groups, P\<0.05.

###### 

Total effective rate of the observation group was significantly higher than that of the control group.

  Groups        Cases   Basic cure (n, %)   Significant progress (n, %)   Progress (n, %)   No change (n, %)   Deterioration (n, %)   Death (n, %)   Total effective rate (n, %)
  ------------- ------- ------------------- ----------------------------- ----------------- ------------------ ---------------------- -------------- --------------------------------------------------------
  Observation   29      8 (27.59)           11 (37.93)                    8 (27.59)         2 (6.90)           0 (0.00)               0 (0.00)       26 (89.66)^[a](#tfn7-br-0-0-692){ref-type="table-fn"}^
  Control       29      4 (13.79)           8 (27.59)                     6 (20.69)         9 (31.03)          2 (6.90)               0 (0.00)       18 (62.07)

Comparison between the observation group and the treatment group, P\<0.05.
